November 14-16 - Takis presented promising data at NeoAntigen Summit in Boston

Dr Fabio Palombo - Cancer Vaccine group leader at Takis - presented at Boston: 

Developing a neoantigen cancer vaccine strategy by plasmid DNA and electroporation 

Cancer vaccines based on neoantigens have rapidly reached the stage of clinical trials. In collaboration with Biogem, Takis Biotech has started a couple of years ago a research program exploring Cancer Neoantigens as potential targets for DNA vaccination. 

Dr Fabio Palombo, declared: "We have explored the use of naked DNA delivered by electroporation (EP).  A pipeline for neoantigen prediction was developed and selected neoantigens inserted in a proprietary plasmid (TK1). Intramuscular delivery of the neoantigen-expressing vector by EP was effective in inducing strong and persistent polyspecific immune responses (CD8⁺ IFN-g⁺ TNF-a⁺) and protecting preclinical models from tumor occurrence."

"The high level of induced immune responses as well as the impact on tumor growth support the development of this technology into a phase I clinical trial. Takis is willing to discuss the neoantigen platform in order to initiate a clinical trial in melanoma and lung cancer patients." - stated Luigi Aurisicchio, CEO/CSO at Takis.

For more info: http://neo-antigen.com/